Skip to main content

Publications

Found 37 results
Author [ Title(Asc)] Year
Filters: First Letter Of Last Name is P and Author is Beth A Payne  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Ryan H, Jones M, Payne BA, Sharma S, Hutfield A, Lee T, et al.. Validating the Performance of the Modified Early Obstetric Warning System Multivariable Model to Predict Maternal Intensive Care Unit Admission. J Obstet Gynaecol Can. 2017;39(9):728-733.e3.  (176.34 KB)
U
Yen T-W, Payne BA, Qu Z, Hutcheon J, Lee T, Magee LA, et al.. Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809.  (269.78 KB)
Ryan H, Sharma S, Magee LA, Ansermino JM, MacDonell K, Payne BA, et al.. The Usefulness of the APACHE II Score in Obstetric Critical Care: A Structured Review. J Obstet Gynaecol Can. 2016;38(10):909-918.  (304.95 KB)
Lim J, Cloete G, Dunsmuir D, Payne BA, Scheffer C, von Dadelszen P, et al.. Usability and Feasibility of PIERS on the Move: An mHealth App for Pre-Eclampsia Triage. JMIR Mhealth Uhealth. 2015;3(2):e37.  (831.85 KB)
Livingston J, Payne BA, Brown M, Roberts J, Côté A-M, Magee LA, et al.. Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014;36(10):870-877.  (1021.64 KB)
T
Ukah V, Payne BA, Karjalainen H, Kortelainen E, Seed P, Conti-Ramsden FInez, et al.. Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia. Pregnancy Hypertens. 2019;15:42-50.  (887.01 KB)
R
Laskin S, Payne BA, Hutcheon J, Qu Z, M Douglas J, Ford J, et al.. The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8.  (370.8 KB)
Payne BA, Hutcheon J, Ansermino JM, Hall D, Bhutta ZA, Bhutta ZA, et al.. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med. 2014;11(1):e1001589.  (353.97 KB)
Firoz T, Makanga P, Nathan H, Payne BA, Magee LA. Reverse innovation in maternal health. Obstet Med. 2017;10(3):113-119.  (710.03 KB)
P
Payne BA, von Dadelszen P, Bhutta ZA, Magee LA, Olalekan A, Sotunsa J, et al.. Protocol 13PRT/9313:The Community Level Interventions for Pre-eclampsia (CLIP) Trials: four prospective cluster randomised controlled trials comparing a package of interventions directed towards improving maternal and perinatal outcomes related to pre-ecl [Internet]. 2019 . https://clinicaltrials.gov/ct2/show/study/NCT01911494?term=01911494&rank=1
Sharma S, Olalekan A, Vidler M, Drebit S, Payne BA, Akeju D, et al.. A process evaluation plan for assessing a complex community-based maternal health intervention in Ogun State, Nigeria. BMC Health Serv Res. 2017;17(1):238.  (925.17 KB)
von Dadelszen P, Firoz T, Donnay F, Gordon R, Hofmeyr J, Lalani S, et al.. Preeclampsia in low and middle income countries-health services lessons learned from the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and Treatment) project. J Obstet Gynaecol Can. 2012;34(10):917-926.  (322.96 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
Ukah V, De Silva D, Payne BA, Magee LA, Hutcheon J, Brown H, et al.. Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123.  (501.41 KB)
Akkermans J, Payne BA, von Dadelszen P, Groen H, de Vries J, Magee LA, et al.. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62.  (317.15 KB)
Ukah V, Hutcheon J, Payne BA, Haslam M, Vatish M, Ansermino JM, et al.. Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237.  (986.49 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Firoz T, Magee LA, Payne BA, Menzies J, von Dadelszen P. The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81.  (233.18 KB)
Lalani S, Firoz T, Magee LA, Sawchuck D, Payne BA, Gordon R, et al.. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223.  (529.81 KB)
Payne BA, Hodgson S, Hutcheon J, Joseph KS, Li J, Lee T, et al.. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8.  (85.31 KB)
O
Millman A, Payne BA, Qu Z, M Douglas J, Hutcheon J, Lee T, et al.. Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714.  (383.37 KB)
Firoz T, Magee LA, MacDonell K, Payne BA, Gordon R, Vidler M, et al.. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210-8; discussion 1220.  (158.15 KB)
M
von Dadelszen P, Magee LA, Payne BA, Dunsmuir D, Drebit S, Dumont G, et al.. Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5.  (662.6 KB)
Bellad M, Vidler M, Honnungar N, A M, Ramadurg U, Charanthimath U, et al.. Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS One. 2017;12(1):e0166623.  (2.12 MB)
Gordon R, Magee LA, Payne BA, Firoz T, Sawchuck D, Tu D, et al.. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163.  (1.42 MB)
I
Magee LA, Sharma S, Nathan H, Adetoro OO, Bellad MB, Goudar S, et al.. The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis. PLoS Med. 2019;16(4):e1002783.  (864.32 KB)
H
Sacoor C, Payne BA, Augusto O, Vilanculo F, Nhacolo A, Vidler M, et al.. Health and socio-demographic profile of women of reproductive age in rural communities of southern Mozambique. PLoS One. 2018;13(2):e0184249.  (3.25 MB)
E
Ukah V, Payne BA, Lee T, Magee LA, von Dadelszen P. External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries. Hypertension. 2017;69(4):705-711.  (149.83 KB)
D
Dunsmuir D, Payne BA, Cloete G, Petersen C, Görges M, Lim J, et al.. Development of mHealth applications for pre-eclampsia triage. IEEE J Biomed Health Inform. 2014;18(6):1857-64.  (300.31 KB)
Payne BA, Ryan H, Bone J, Magee LA, Aarvold A, Ansermino JM, et al.. Development and internal validation of the multivariable CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) clinical risk prediction model. Crit Care. 2018;22(1):278.  (961.71 KB)
Payne BA, Groen H, Ukah V, Ansermino JM, Bhutta ZA, Grobman W, et al.. Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21.  (505.41 KB)
C
Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, et al.. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.  (322.85 KB)
A
Payne BA, Magee LA, von Dadelszen P. Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62.  (178.71 KB)
Ukah V, Payne BA, Hutcheon J, Ansermino JM, Ganzevoort J, Thangaratinam S, et al.. Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia. Hypertension. 2018;71(4):659-665.  (237.99 KB)
Payne BA, Kyle PM, Lim K, Lisonkova S, Magee LA, Pullar B, et al.. An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertens. 2013;3(3):166-71.  (232.97 KB)
Payne BA, Hutcheon J, Dunsmuir D, Cloete G, Dumont G, Hall D, et al.. Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can. 2015;37(1):16-24.  (1.11 MB)
Kozic J, Benton S, Hutcheon J, Payne BA, Magee LA, von Dadelszen P. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004.  (280.12 KB)